Atara Biotherapeutics Gets a Buy Rating from Jefferies

By Austin Angelo

In a report released today, Maury Raycroft from Jefferies resumed coverage with a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA) and a price target of $30. The company’s shares opened today at $14.65.

According to TipRanks.com, Raycroft is a 3-star analyst with an average return of 10.5% and a 100.0% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Sangamo Biosciences, and Alnylam Pharma.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $38.50.

The company has a one year high of $25.73 and a one year low of $11.80. Currently, Atara Biotherapeutics has an average volume of 281.3K.

Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage biopharmaceutical company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.,0DHGMT-E